Suggested remit: To appraise the clinical and cost effectiveness of enfortumab vedotin within its marketing authorisation for treating locally advanced or metastatic urothelial cancer after 2 therapies.
Following on from advice received from the company, who at this time has not provided an evidence submission, the timelines for this appraisal are currently to be confirmed and therefore the appraisal is suspended.
 
Status Suspended
Process STA 2018
ID number 3845

Provisional Schedule

Expected publication 09 March 2022

Project Team

Project lead Gavin Kenny

Email enquiries

Consultees

Companies sponsors Astellas Pharma Ltd (enfortumab vedotin)
Others Department of Health and Social Care
  NHS England
  NHS Sheffield CCG
  NHS Wokingham CCG
  Welsh Government
Patient carer groups Action Bladder Cancer UK
  Black Health Agency
  Bladder and Bowel UK
  Cancer 52
  Cancer Black Care
  Cancer Equality
  Fight Bladder Cancer
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Pelican Cancer Foundation
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
Professional groups Association of Cancer Physicians
  British Association of Urological Nurses
  British Association of Urological Surgeons
  British Geriatrics Society
  British Gynaecological Cancer Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Society of Urogenital Radiology
  British Society of Urogynaecology
  British Uro-Oncology Group
  Cancer Research UK
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society
  Urology Foundation

Commentators

Associated public health groups • Public Health England
  • Public Health Wales
Comparator companies • Accord Healthcare (docetaxel, paclitaxel)
  • Celgene (paclitaxel)
  • Hospira UK (docetaxel, paclitaxel)
  • Seacross Pharmaceuticals (docetaxel, paclitaxel)
  • Teva UK (paclitaxel)
General commentators • All Wales Therapeutics and Toxicology Centre
  • Allied Health Professionals Federation
  • Board of Community Health Councils in Wales
  • British National Formulary
  • Care Quality Commission
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland
  • Medicines and Healthcare products Regulatory Agency
  • National Association of Primary Care
  • National Pharmacy Association
  • NHS Alliance
  • NHS Confederation
  • Scottish Medicines Consortium
  • Welsh Health Specialised Services Committee
Relevant research groups • Cochrane Urology
  • Genomics England
  • Heart Research UK
  • Institute of Cancer Research
  • MRC Clinical Trials Unit
  • National Cancer Research Institute
  • National Cancer Research Network
  • National Institute for Health Research
  • Urothelial Cancers Research Group, Leeds Institute of Cancer & Pathology

Timeline

Key events during the development of the guidance:

Date Update
12 July 2021 Suspended. Following on from advice received from the company, who at this time has not provided an evidence submission, the timelines for this appraisal are currently to be confirmed and therefore the appraisal is suspended.
28 April 2021 Invitation to participate
05 February 2021 - 05 March 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance